已收盤 09-20 16:00:00 美东时间
+0.040
+0.51%
Updated results from the HIMALAYA Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) plus IMJUDO®(tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five
09-16 19:02
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an inde...
09-12 01:00
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider ...
09-11 18:25
Zimcal Disturbed by Medallion Financial’s Second Quarter Results
08-21 03:31
In a report released today, Michael Grondahl from Northland Securities maintain...
08-01 21:29
Medallion Financial (NASDAQ:MFIN) declares $0.10/share quarterly dividend, in line with previous. Forward yield 4.95% Payable Aug. 30; for shareholders of record Aug. 15; ex-div Aug. 15. See MFIN Divi...
07-31 20:56
Medallion Financial Q2 Net Interest Margin 8.42%
07-31 04:03
Medallion Financial Corp. Reports 2024 Second Quarter Results
07-31 04:03